Cumulative dosage of pegylated-interferon α and ribavirin in treatment arms by HCV-genotype
| HCV genotype 1 | HCV genotype 2/3 | |||||
| SOC (n=32), N (%) | SOC + B12 (n=32), N (%) | p Value | SOC (n=15), N (%) | SOC + B12 (n=15), N (%) | p Value | |
| 4th Week | ||||||
| Peg-IFNα2 <80% | – | 1/32 (3) | NS | – | – | NS |
| Peg-IFNα2 <50% | – | – | NS | – | – | NS |
| RBV <80% | 1/32 (3) | – | NS | – | – | NS |
| RBV <50% | – | – | NS | – | – | NS |
| Treatment discontinuation | – | – | NS | – | – | NS |
| Peg-IFNα2 >80% + RBV >80% | 31/32 (97) | 31/32 (97) | NS | 15/15 (100) | 15/15 (100) | NS |
| 12th Week | ||||||
| Peg-IFNα2 <80% | – | 1/32 (3)* | NS | – | – | NS |
| Peg-IFNα2 <50% | – | 1/32 (3) | NS | 1/15 (7)* | – | NS |
| RBV <80% | 2/32 (6%) | 2/32 (6) | NS | 1/15 (7)* | – | NS |
| RBV <50% | – | 2/32 (6)* | NS | 1/15 (7)* | – | NS |
| Treatment discontinuation | – | – | NS | – | – | NS |
| Peg-IFNα2 >80% + RBV >80% | 30/32 (94) | 26/32 (81) | NS | 12/15 (80) | 15/15 (100) | NS |
| 24th Week | ||||||
| Peg-IFNα2 <80% | – | – | NS | – | – | NS |
| Peg-IFNα2 <50% | 2/32 (6) | 2/29 (7) | NS | – | – | NS |
| RBV <80% | 3/32 (9) | 4/29 (14) | NS | – | – | NS |
| RBV <50% | 1/32 (3) | – | NS | – | – | NS |
| Treatment discontinuation | 6/32 (19) | 4/29 (14) | NS | – | – | NS |
| Peg-IFNα2 >80% + RBV >80% | 20/32 (63) | 19/29 (66) | NS | 12/12 (100) | 15/15 (100) | NS |
| 48th Week | ||||||
| Peg-IFNα2 <80% | – | – | NS | |||
| Peg-IFNα2 <50% | 3/32 (9) | 2/29 (7) | NS | |||
| RBV <80% | 5/32 (16) | 4/29 (14) | NS | |||
| RBV <50% | 3/32 (9) | 1/29 (3) | NS | |||
| Treatment discontinuation | – | 1/29 (3) | NS | |||
| Peg-IFNα2 >80% + RBV >80% | 15/32 (47) | 17/29 (59) | NS | |||
↵* Dropout.
HCV, hepatitis C virus; peg-IFNα2, pegylated-interferon-α2; RBV, ribavirin; SOC, standard of care.